Eva Dahlén

Title: **Eva Dahlén: A Pioneer in Bispecific Polypeptide Innovation**

Introduction

Eva Dahlén, an innovative inventor based in Lund, Sweden, has made significant contributions to the field of biomedicine. With her groundbreaking patent, she has opened new avenues for cancer treatment through the development of bispecific polypeptides.

Latest Patents

One of Eva’s notable patents is for bispecific polypeptides against CD137. This invention features bispecific polypeptides that comprise a first binding domain, designated B1, which specifically binds to CD137, and a second binding domain, designated B2, which targets a tumour cell-associated antigen. Additionally, the patent includes pharmaceutical compositions derived from these bispecific polypeptides and their applications in medicine, potentially transforming therapeutic strategies in oncology.

Career Highlights

Eva currently works at Alligator Bioscience AB, a company renowned for its innovative approach to cancer immunotherapy. Her expertise and creativity have enabled her to make impactful strides in the biotechnology sector, underscoring her status as a prominent inventor in her field.

Collaborations

Throughout her career, Eva has collaborated with talented coworkers such as Peter Ellmark and Christina Furebring. These partnerships highlight the importance of teamwork in advancing scientific research and developing pioneering medical therapies.

Conclusion

Eva Dahlén's contributions to the field of bispecific polypeptides represent a significant advancement in medical science. With her innovative spirit and dedication, she continues to pave the way for future discoveries in cancer treatment, inspiring researchers and inventors alike.